Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →BioNTech is broadening its cancer immunotherapy strategy with a deal to acquire Kite Pharma's solid tumor neoantigen T-cell receptor R&D platform and a…
Gilead Sciences said its Kite cell therapy unit will divest its solid tumor T-cell receptor research and development platform along with a manufacturing…
BioNTech said it will stop manufacturing cell therapies at its Gaithersburg, Maryland site -- acquired from Gilead's Kite Pharma in 2021 -- by the end of…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
BioNTech acquired Kite's individualized solid-tumor neoantigen TCR discovery platform and clinical manufacturing facility in Gaithersburg, MD, from Gilead. Announced July 19, 2021 and closed August 4, 2021; financial terms were not disclosed, with BioNTech later citing ~$250M in associated transaction costs (Q3 2021). The deal gave BioNTech a TCR-based cell-therapy capability and its first U.S. manufacturing footprint to pair with its mRNA cancer-vaccine platforms, while letting Gilead's Kite refocus on hematologic CAR-T (Yescarta, Tecartus). Post-close outcome: in June 2025 BioNTech announced it would cease cell-therapy manufacturing at the Gaithersburg site by end of 2025 and lay off 63 technical-operations staff, after dropping its lead CLDN6 CAR-T candidate BNT211 in germ-cell/testicular tumors following a Phase 1 signal-seeking readout. BNT211 development continues in other CLDN6-positive solid tumors, and the site is being realigned to other portfolio priorities (including ADCs such as BNT323), reflecting BioNTech's strategic pivot away from cell therapy toward mRNA and antibody-drug-conjugate modalities.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| BioNTech SE / Kite Pharma (Gilead Sciences) (this deal) | 2021 | $250M | — |
| BioNTech SE / Duality Biologics (Suzhou) Co. Ltd. | 2023 | $1.7B | — |
| BioNTech SE / Biotheus Inc. (Pumai Biotechnology) | 2024 | $950M | — |
| BioNTech SE / CureVac N.V. | 2025 | $1.2B | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
← Browse all deals · How we score deals
More: 2021 deals · BioNTech SE deals · Oncology deals